4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸
| 中文名称 | 4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 |
|---|---|
| 中文同义词 | 转录因子STAT3小分子抑制剂(BP-1-102);BP-1-102游离态;化合物BP-1-102;4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸;化合物BP-1-102,10 MM DMSO 溶液;BP-1-102(BP1-102) |CAS 1334493-07-0;化合物:BP-1-102 CAS:1334493-07-0;BP-1-102试剂 |
| 英文名称 | BP-1-102 |
| 英文同义词 | BP-1-102;4-(N-(4-Cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydr;STAT3 Inhibitor XVIII, BP-1-102;BP-1-102; BP1-102; BP 1-102.;4-(N-(4-cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydroxybenzoic acid;STAT3 Inhibitor XVIII;STAT3 INHIBITOR XVIII;BP1-102;BP 1-102;Benzoic acid, 4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-2-hydroxy- |
| CAS号 | 1334493-07-0 |
| 分子式 | C29H27F5N2O6S |
| 分子量 | 626.59 |
| EINECS号 | |
| 相关类别 | 细胞生物学试剂;API |
| Mol文件 | 1334493-07-0.mol |
| 结构式 |  |
4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 性质
| 沸点 | 749.2±70.0 °C(Predicted) |
|---|---|
| 密度 | 1.474±0.06 g/cm3(Predicted) |
| 储存条件 | Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | DMSO:15.0(最大浓度 mg/mL);23.9(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 3.15±0.10(Predicted) |
| 颜色 | 白色至米白色 |
| InChIKey | WNVSFFVDMUSXSX-UHFFFAOYSA-N |
| SMILES | C(O)(=O)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(C2=C(F)C(F)=C(F)C(F)=C2F)(=O)=O)=O)C=C1O |
|
STAT3 6.8 μM (IC 50 ) |
BP-1-102 binds Stat3 with an affinity K D of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro , with an IC 50 value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8.
Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth.
![Phenylmethyl 4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-2-(phenylmethoxy)benzoate](/CAS/20210305/GIF/1334493-48-9.gif)
1334493-48-9
1334493-07-0
通用方法：将苄基保护的水杨酸（1当量）溶于搅拌的甲醇/四氢呋喃（1:1，v/v，0.1M）混合溶剂中。在彻底脱气后，谨慎加入10%钯/碳催化剂（10mg/mmol）。向溶液中通入氢气鼓泡5分钟，随后在氢气氛围下持续搅拌反应3小时。反应完成后，排除氢气，通过过滤移除钯催化剂，并在减压条件下浓缩滤液。
参考文献：
[1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 18, p. 5605 - 5609
[2] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 11, p. 1102 - 1107
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 18, p. 7190 - 7200
安全信息
| WGK Germany | WGK 2 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-100493 | 4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 BP-1-102 | 1334493-07-0 | 5mg | 950元 |
| 2026/06/05 | HY-100493 | 4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 BP-1-102 | 1334493-07-0 | 10mM * 1mLin DMSO | 1310元 |